"シオノギ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonShionogi & Co. (SGIOF) Price Target Increased by 11.63% to 17.40 - Nasdaq
Shionogi & Co. (SGIOF) Price Target Increased by 11.63% to 17.40 Nasdaq
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the N...
The Power to Create Medicines That Reach Patients—Passing SHIONOGI’s Baton of Innovation to the Next Generation Shionogi Inc.
Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth - Bloomberg.com
Shionogi Lifts Profit Outlook on HIV Royalties, Overseas Growth Bloomberg.com
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek - Yahoo Finance
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek Yahoo Finance
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention Contagion Live
Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug - MarketWatch
Yomiuri: Nobel Prize Winner, Shionogi Jointly Developing New Cancer Drug MarketWatch
BRIEF—Shionogi launches new form of Xofluza - The Pharma Letter
BRIEF—Shionogi launches new form of Xofluza The Pharma Letter
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure Business Wire
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech
Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program Fierce Biotech
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners - Imperial College...
Global pharmaceutical company Shionogi joins Paddington Life Sciences Partners Imperial College Healthcare NHS Trust
BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology
BioVersys and Shionogi agree to develop ansamycin leads Pharmaceutical Technology
Shionogi to buy Japan Tobacco's pharma units for over $1B - FirstWord Pharma
Shionogi to buy Japan Tobacco's pharma units for over $1B FirstWord Pharma
Accelerating drug discovery with AI innovation - SAS: Data and AI Solutions
Accelerating drug discovery with AI innovation SAS: Data and AI Solutions
The Bull Case For Shionogi (TSE:4507) Could Change Following Cost-Driven Profit Outlook Amid Reve...
The Bull Case For Shionogi (TSE:4507) Could Change Following Cost-Driven Profit Outlook Amid Revenue Slowdown simplywall.st
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP Infectious Disease Special Edition
Enrollment Update - Shionogi Inc.
Enrollment Update Shionogi Inc.
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculou...
Shionogi (TSE:4507): Unpacking Valuation After Upbeat Forecast, Fetroja® Results, and New Dividen...
Shionogi (TSE:4507): Unpacking Valuation After Upbeat Forecast, Fetroja® Results, and New Dividend simplywall.st
Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma
Shionogi strikes research and option deal with BioVersys for antibacterial assets FirstWord Pharma
IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol A...
Analyst Estimates: Here's What Brokers Think Of Shionogi & Co., Ltd. (TSE:4507) After Its Half-Ye...
Analyst Estimates: Here's What Brokers Think Of Shionogi & Co., Ltd. (TSE:4507) After Its Half-Year Report simplywall.st
Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech
Bioversys, Shionogi in CHF529M lung infection collaboration BioWorld MedTech
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge JAPAN Forward
Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter
Shionogi pushes 2030 vision forward with $1 billion acquisition The Pharma Letter
Shionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion - TipRanks
Shionogi & Co. Reports Steady Q2 Earnings Amid Strategic Expansion TipRanks
Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients - 2 Minute Medicine
Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients 2 Minute Medicine
Shionogi inks new hearing loss research deal with Cilcare - The Pharma Letter
Shionogi inks new hearing loss research deal with Cilcare The Pharma Letter
Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs - Nikkei Asia
Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs Nikkei Asia
Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain - TipRanks
Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain TipRanks
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs Bloomberg.com
Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech
Shionogi to acquire Japan Tobacco pharma companies for $1.1B BioWorld MedTech
BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter
BioVersys joins forces with Shionogi on ansamycin development The Pharma Letter
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion Reuters
Shionogi’s Steady Earnings Came With A Dividend Sweetener - Finimize
Shionogi’s Steady Earnings Came With A Dividend Sweetener Finimize
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults Fierce Biotech
Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges - TipRanks
Shionogi Reports Mixed Q2 FY 2025 Results Amid Revenue Challenges TipRanks
Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum
Shionogi puts up to $600m behind BioVersys antibiotics pharmaphorum
Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business - TipRanks
Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business TipRanks
Gareth Morgan Named President of Qpex Biopharma, Inc. - Business Wire
Gareth Morgan Named President of Qpex Biopharma, Inc. Business Wire
Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary - TipRanks
Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary TipRanks
Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy
Eyes on Asia: Chugai, Mabwell, Shionogi BioXconomy
Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - news.bloomberglaw.com
Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug news.bloomberglaw.com
BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech
BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants BioWorld MedTech
Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum
Shionogi aims to buy tobacco giant's pharma unit for $1bn pharmaphorum
Shionogi & Co., Ltd. Announces Management Appointments - MarketScreener
Shionogi & Co., Ltd. Announces Management Appointments MarketScreener
Ceolia takes over from Shionogi in marketing of Actair in Japan - The Pharma Letter
Ceolia takes over from Shionogi in marketing of Actair in Japan The Pharma Letter
Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology
Shionogi awarded $375m from HHS for preventative Covid-19 injectable Pharmaceutical Technology
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - Business ...
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan Business Wire
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Clinical Trials A...
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial Clinical Trials Arena
Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary - The Globe and...
Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary The Globe and Mail
Shionogi Initiates First-Ever Human Study Testing Therapy for Ultra-Rare Jordan Syndrome - Neurol...
Shionogi Initiates First-Ever Human Study Testing Therapy for Ultra-Rare Jordan Syndrome Neurology Live
Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch
Swiss firm BioVersys signs deal with Shionogi for antibiotics research SWI swissinfo.ch
Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter
Shionogi files in Japan to expand pediatric use of COVID-19 antiviral The Pharma Letter
Drugmakers announce encouraging new antibiotic data at IDWeek - CIDRAP
Drugmakers announce encouraging new antibiotic data at IDWeek CIDRAP
The Leadership Connection - BOSS Publishing
The Leadership Connection BOSS Publishing
Shionogi gets approval in Japan for ADHD digital therapeutic - pharmaphorum
Shionogi gets approval in Japan for ADHD digital therapeutic pharmaphorum
BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases - BioSpect...
BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases BioSpectrum Asia
Shionogi Investigational RSV Antiviral Reaches Primary Endpoint for Phase 2 Trial - Contagion Live
Shionogi Investigational RSV Antiviral Reaches Primary Endpoint for Phase 2 Trial Contagion Live
Apnimed Provides Clinical Updates for Multiple Product Candidates - PR Newswire
Apnimed Provides Clinical Updates for Multiple Product Candidates PR Newswire
Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal - Nikkei Asia
Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal Nikkei Asia
Rating Change Observations: Shionogi & Co. upgraded, NRI downgraded, among others. - 富途牛牛
Rating Change Observations: Shionogi & Co. upgraded, NRI downgraded, among others. 富途牛牛
Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...
Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma - Bloomberg.com
Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma Bloomberg.com
Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate - Sleep Review
Apnimed Acquires Global Rights to Additional Sleep Apnea Drug Candidate Sleep Review
Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya - B...
Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya BioSpectrum Asia
Japan's Shionogi-Torii Pharmaceutical merger conditionally cleared by JFTC - MLex
Japan's Shionogi-Torii Pharmaceutical merger conditionally cleared by JFTC MLex
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...
Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia
Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand BioSpectrum Asia
Shionogi & Co (4507 JP): Muted 1H Result; Solid HIV Business Leads FY Profit Guidance Raise - Sma...
Shionogi & Co (4507 JP): Muted 1H Result; Solid HIV Business Leads FY Profit Guidance Raise Smartkarma
BARDA to fund development of COVID preventive drug - CIDRAP
China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi - Yi...
China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi Yicai Global
His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone ...
His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone CalMatters
Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter
Nxera and Shionogi launch Quviviq in Japan The Pharma Letter
A Pill to Prevent COVID-19 Shows Promise - Time Magazine
A Pill to Prevent COVID-19 Shows Promise Time Magazine
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - Yahoo Finance
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia Yahoo Finance
Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much mo...
Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much more statnews.com
Apnimed doses first subject in trial for sleep apnoea with central component - Clinical Trials Arena
Apnimed doses first subject in trial for sleep apnoea with central component Clinical Trials Arena
Top Japanese firms steer USD1.1bn Japan pharma takeover - Law.asia
Top Japanese firms steer USD1.1bn Japan pharma takeover Law.asia
Ensitrelvir Effective as Oral Antiviral for Postexposure Prophylaxis Against COVID-19 - Pharmacy ...
Ensitrelvir Effective as Oral Antiviral for Postexposure Prophylaxis Against COVID-19 Pharmacy Times
Can a Daily Pill Stop a Constant Killer in Its Tracks? - Bloomberg.com
Can a Daily Pill Stop a Constant Killer in Its Tracks? Bloomberg.com
Preparing Europe for the next cross-border health threats, COVID lessons unpacked - Euractiv
Preparing Europe for the next cross-border health threats, COVID lessons unpacked Euractiv
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - The AI Jo...
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan The AI Journal
FAERS Analysis Provides New Insights on Cefiderocol Adverse Effects - Pharmacy Times
FAERS Analysis Provides New Insights on Cefiderocol Adverse Effects Pharmacy Times
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment Precedence Research
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs ...
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs Fierce Pharma
hVIVO trial validates Shionogi's RSV candidate with 89% viral load reduction - Vox Markets
hVIVO trial validates Shionogi's RSV candidate with 89% viral load reduction Vox Markets
SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...
Masahiro Fujita - Shionogi Inc.
Masahiro Fujita Shionogi Inc.
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...
Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value Shionogi Inc.
Even More Studies From IDWeek 2024 to Improve Lives: CSL Seqirus and Shionogi - Infection Control...
Even More Studies From IDWeek 2024 to Improve Lives: CSL Seqirus and Shionogi Infection Control Today
Clinical trial marks key milestone in fight against antibiotic resistance - UQ News
Clinical trial marks key milestone in fight against antibiotic resistance UQ News
Nathan McCutcheon - Shionogi Inc.
Nathan McCutcheon Shionogi Inc.
Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.
Notice of Head Office Relocation｜ 塩野義製薬 Shionogi Inc.
Improving affordability for patients in need - Shionogi Inc.
Improving affordability for patients in need Shionogi Inc.
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...
NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 National Institutes of Health (.gov)
Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology
Shionogi to acquire Qpex Biopharma for $140m Pharmaceutical Technology
Message from Top Management - Shionogi Inc.
Message from Top Management Shionogi Inc.
What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd...
What we stand for: Takeki Uehara | Clinical Development Vision and Strategy | Shionogi & Co., Ltd. Shionogi Inc.
History - Shionogi Inc.
History Shionogi Inc.
Beyond CPAP: Apnimed’s Potential To Transform Sleep Apnea Management - Citeline News & Insights
Beyond CPAP: Apnimed’s Potential To Transform Sleep Apnea Management Citeline News & Insights